(Total Views: 840)
Posted On: 11/12/2021 3:29:06 AM
Post# of 153913
C, Evil has it right, but there was more.
The NSF VP also said he could not understand why Amarex was keeping the data from CYDY. Admission of guilt:
Also: the FDA gave a letter to Cytodyn showing Amarex failed to file annual IND annual reports.
Also: from Sidley court documents sent in 3 days ago, page 13, point 39:
Backdating is of course a pretty serious offense.
I think there's more I've forgotten. If you read the posts of @Aaron on the YMB board, he's very good -- comprehensive, but also fair.
The short version is that I don't see how Amarex, and even NSF, can get away without extensive damages. IMO, more than we've paid them already, which is $60 million. Think about how the last year would have been different if they'd correctly filed the HIV BLA -- no toxic loans, NASDAQ listing, institutional investment, off-label use. It's not a small difference.
The NSF VP also said he could not understand why Amarex was keeping the data from CYDY. Admission of guilt:
Quote:
Martin Lush wrote in a June 9, 2021 email to CytoDyn that “[y]ou own every piece of data generated by the CRO. . . . I’m just trying to better understand why KK [Kazem Kazempour, Amarex’s CEO] is refusing to release non executable data files since this is usually a contractual requirement."
Also: the FDA gave a letter to Cytodyn showing Amarex failed to file annual IND annual reports.
Also: from Sidley court documents sent in 3 days ago, page 13, point 39:
Quote:
"Amarex...has backdated certain letters regarding... monitoring (In violation of FDA regulations)"
Backdating is of course a pretty serious offense.
I think there's more I've forgotten. If you read the posts of @Aaron on the YMB board, he's very good -- comprehensive, but also fair.
The short version is that I don't see how Amarex, and even NSF, can get away without extensive damages. IMO, more than we've paid them already, which is $60 million. Think about how the last year would have been different if they'd correctly filed the HIV BLA -- no toxic loans, NASDAQ listing, institutional investment, off-label use. It's not a small difference.
(21)
(0)
